Molecular Biology of Astroblastoma-An Essential Review

Abstract

Astroblastoma is a rare, well-circumscribed neuroepithelial central nervous system tumor that predominantly affects children, young adults, and females, accounting for 0.45% to 2.8% of all primary brain gliomas. At the molecular level, its defining pathognomonic hallmark is the rearrangement of the MN1 (Meningioma 1) gene located on chromosome 22q12.1. This genetic alteration typically results in oncogenic fusions with various partner genes, most frequently BEND2 or CXXC5, which serve as crucial diagnostic bio-markers readily detectable via Fluorescence In Situ Hybridization (FISH) analysis. Advanced molecular profiling further categorizes these neoplasms into a specific, distinct "astroblastoma, MN1-altered" DNA methylation class. This unique epigenetic signature is essential for separating true astroblastomas from morphological mimics, such as ependymomas or glioblastomas, which can occasionally exhibit focal astroblastic patterns. Beyond MN1 rearrangements, Comparative Genomic Hybridization (CGH) has identified other recurrent large scale chromosomal copy number variations, most notably copy number gains on chromosome arm 20q and chromosome 19, which frequently co-occur across both well-differentiated and malignant variants. Histopathologically, the tumor is characterized by classic astroblastic perivascular pseudorosettes formed by tumor cells with broad, tapering cytoplasmic processes radiating toward vessels, accompanied by prominent stromal and perivascular hyalinization and a pushing, non infiltrative border. Immunohistochemically, astroblastomas demonstrate consistent and distinct positivity for Epithelial Membrane Antigen (EMA) and Glial Fibrillary Acidic Protein (GFAP), along with variable immunoreactivity for S-100 protein, vimentin, OLIG2, and D2-40, supporting a transitional histogenesis between astrocytic and ependymal lineages. Clinical management and prognosis are heavily driven by histopathological grading. While low-grade variants carry a favorable prognosis, high-grade or malignant variants exhibit prominent anaplasia. These malignant phenotypes are characterized molecularly and cellularly by hypercellularity, brisk mitotic activity (>5 mitoses per 10 high-power fields), pseudopalisading necrosis, microvascular proliferation, and nuclear pleomorphism. Integrating these precise molecular signatures with established immunophenotypic profiles is now mandatory to secure an accurate diagnosis, differentiate them from tanycytic ependymomas, and guide therapeutic strategies including complete surgical resection and targeted adjuvant radiotherapy.

Keywords: Astroblastoma; Brain Neoplasms; Gliomas; Molecular Characterization; Gene Fusion

Citation

Chrysanthakopoulos NA, Vazintari V. Molecular Biology of Astroblastoma-An Essential Review. WebLog J Oncol. wjo.2026.h1406. https://doi.org/10.5281/zenodo.22168886